Does GLP-1 Reduce Hot Flashes? What the Research Actually Shows

No GLP-1 medication is approved to treat hot flashes, and none should be started for that purpose alone — but the question is more interesting than a flat 'no.' GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are approved for type 2 diabetes and weight management, not menopause symptoms. Any effect they have on hot flashes appears to be indirect, driven by weight loss rather than a direct action on the temperature-regulating pathways in the brain.

Hot flashes — medically called vasomotor symptoms (VMS) — are triggered by changes in the brain's hypothalamus as estrogen declines, which narrows the range of temperature the body tolerates before triggering a flush. Body fat influences this system, which is the crucial link. So while GLP-1s were not designed to touch hot flashes, the substantial weight loss they cause may still move the needle for some women. Understanding that distinction matters, because it sets realistic expectations: a GLP-1 might help, but it is not a menopause drug.

Higher body weight and body fat are associated with more frequent and more severe hot flashes, according to the landmark Study of Women's Health Across the Nation (SWAN). Earlier theories held that fat tissue insulated the body and worsened heat retention; SWAN and later research refined this, showing that greater adiposity correlates with a higher burden of vasomotor symptoms during the menopause transition.

Fat tissue is also hormonally active — it produces inflammatory signals and affects how the body handles temperature regulation and hormone metabolism. This is why weight is considered a modifiable factor in hot-flash severity, unlike age or genetics. It is the mechanistic reason researchers hypothesize that weight loss, however it is achieved, might ease vasomotor symptoms. This connection also overlaps with the broader metabolic story of midlife — our guide on [why belly fat shifts in menopause](/blog/glp1-menopause-visceral-fat-why-belly-fat-shifts) explains how estrogen loss redistributes fat and why that matters for overall health.

Yes — several studies of lifestyle-based weight loss have found that reducing body weight can decrease the frequency and severity of hot flashes. A well-known behavioral weight-loss trial published in the journal *Menopause* found that women who lost weight through diet and activity reported improvement in their vasomotor symptoms compared with those who did not. The effect was modest but real.

This is the strongest evidence supporting the idea that GLP-1s might help hot flashes indirectly: if losing weight eases vasomotor symptoms, and GLP-1s are among the most effective tools for weight loss, then a benefit is plausible. However, most of this evidence comes from diet-and-exercise weight loss, not GLP-1 trials specifically, so we should be cautious about assuming the effect transfers identically. The mechanism (less body fat) is the same, but rapid pharmacological weight loss has not been rigorously tested for hot-flash outcomes. For women managing both weight and menopause, our guide to [starting a GLP-1 in perimenopause](/blog/starting-glp1-in-perimenopause-is-it-worth-it) weighs the broader trade-offs.

GLP-1-specific research on hot flashes is still limited and early, so the honest answer is that we do not yet have large, high-quality trials proving GLP-1s reduce vasomotor symptoms. What we have is a combination of strong indirect evidence (the weight-loss link) and a growing number of anecdotal reports from women who notice fewer or milder hot flashes after starting a GLP-1.

Researchers are actively interested in the intersection of GLP-1s and menopause — including work from institutions like Weill Cornell examining how these drugs affect midlife women — but hot flashes specifically have not been a primary endpoint in the major obesity trials (STEP, SURMOUNT). It is worth noting that some women may experience the opposite: GLP-1 side effects like [night sweats or sleep disruption](/blog/sleep-on-glp1-during-menopause-fixing-restless-nights) can be confused with hot flashes. The bottom line is that a GLP-1 may help your hot flashes as a side benefit of weight loss, but you should not rely on it as your hot-flash treatment. If vasomotor symptoms are your main concern, proven therapies exist.

The most effective proven treatment for hot flashes is hormone therapy (HRT), which replaces declining estrogen and can reduce vasomotor symptoms by 75% or more. For women who cannot or prefer not to use hormones, non-hormonal medications now offer strong alternatives, including two newer drugs that target the brain pathway behind hot flashes directly.

Proven and emerging options include:

• •Hormone therapy (HRT) — the gold standard, most effective for moderate to severe symptoms
• •Fezolinetant (Veozah) — an FDA-approved non-hormonal NK3-receptor blocker; see our [Veozah guide](/blog/veozah-fezolinetant-nonhormonal-hot-flash-treatment-explained)
• •Elinzanetant (Lynkuet) — a newer dual-receptor non-hormonal option; see our [Lynkuet guide](/blog/lynkuet-elinzanetant-nonhormonal-hot-flash-treatment-explained)
• •SSRIs/SNRIs — certain antidepressants reduce hot flashes for some women
• •Lifestyle measures — layered clothing, cooling the bedroom, limiting alcohol and spicy triggers

If you are on or considering a GLP-1 and still struggling with hot flashes, the smart move is to treat the two issues appropriately: use the GLP-1 for weight and metabolic health, and use a proven vasomotor therapy for the flashes. Discuss the combination with your clinician — they can be used together safely for most women.